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Abstract
Background. There is strong evidence from a range of long-
term conditions of improved outcomes where patients are
involved in self-management. Against this background, the
international trend for home dialysis continues to decline,
with centre-based haemodialysis continuing its dominance.
Methods. An opinion-based commentary exploring prac-
tice patterns and drivers for home dialysis internationally.
Data are drawn from a number of sources including the
2010 United States Renal Data System report.
Results. Drivers behind the use of home dialysis are com-
plex including factors relating to the patient and their carers,
health care team, health care system, geography and cultural
factors. There are important examples where local champions
or public health initiatives have had a positive impact on the
use of home dialysis; however, in many settings significant
barriers remain. Better systems for giving patient informa-
tion, shared decision making and involving patients in their
own care may have the potential to act as a driver for change.
Conclusion. Centre-based haemodialysis continues to dom-
inate renal replacement therapy internationally with notable
exceptions. Such dominance suggests that most patients
worldwide do not get much choice when it comes to modality
selection.
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The 2010 United States Renal Data System (USRDS) report
[1] provides valuable information from 2008 on international
trends in dialysis and transplantation. Notable variations
across the world are seen—with the highest prevalence of
end-stage renal disease (ESRD) being seen in Japan and
Taiwan at 2000 cases per million of the population (p.m.p)
and at the other end of the spectrum just over 100 p.m.p for
Bangladesh and the Philippines. Clearly, the incidence of
treatment guided by available funding is not the same as
the incidence of the disease itself. Indeed, incident renal
replacement therapy (RRT) rates are more often related to
macroeconomic and renal service factors than measured
demographic or general population health status factors
[2]. The prevalence of functioning renal transplants ranges
from >500 p.m.p in Norway, USA and Spain to very low
rates in emerging countries, and transplantation activity
clearly impacts on the demographics of the dialysis popula-
tion in a particular country. There are important differences
in the incidence of diabetes as a cause of ESRD contributing
nearly 60% in Mexico and ~20% in the UK, and although
age and co-morbidity is not reported, these will also be sub-
ject to considerable variation.
It is therefore not surprising that against this heterogeneous
background, there are wide variations in the use of home
dialysis. Centre-based haemodialysis (HD) is dominant, with
only 9 countries of the 36 that were included reporting home
therapies for >20% of prevalent dialysis patients. These are
Canada, Netherlands, Iceland, Finland, Denmark, Australia,
New Zealand, Mexico and Hong Kong, in order of increasing
prevalence. In the UK, a declining trend meant that home
dialysis fell to <20% for the first time in 2008. Among
those nine countries, peritoneal dialysis (PD) is the main home
therapy with a prevalence of 80% of dialysis in Hong Kong
and ~65% in Mexico, and even in the countries in which
home haemodialysis (HHD) is popular PD is more common.
The prevalence of HHD was 15.6% for New Zealand and
9.4% for Australia, with Denmark reporting 4.6%, Finland
4%, Sweden 2.8%, Netherlands 2.4% and UK 2.1%. The only
country with increased prevalent HHD over the last 5 years
when reported as a percentage of all dialysis was Denmark,
demonstrating an impressive doubling during that period.
Equally, no country reported increased use of PD during
that period. Of course, several regions where there is sig-
nificant growth in dialysis are not included in the USRDS
report, including India, China and the Middle East.
These data obscure trends from individual centres or re-
gions where clinical champions have led expansion in home
therapies. Indeed, this supplement of NDT Plus is part of such
a renaissance and there is some evidence of a reverse in the
declining trend in HHD in a few countries. Increases in ab-
solute numbers on home modalities are obscured by more
rapid simultaneous growth in centre-based dialysis and thus
the way the data is reported is important. For example, when
prevalence is reported as patients per million of the population
rather than as percentage of patients on dialysis, increases
over recent years are revealed in New Zealand, Canada and
Finland [3]. In New Zealand, increased HHD has been con-
tributed to by the use of shared un-staffed houses in Auckland
which leads to a discussion around the definition of HHD.
Indeed, self-care dialysis facilities are used in Belgium but not
reported as HHD [4].
Potential reasons for the wide variation in the usage of
home therapies have been discussed in detail [3, 5]. These
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can be categorized into factors relating to the patient (includ-
ing demographic factors, primary disease and co-morbidity),
the health care team, the arrangements of health care pro-
vision including reimbursement and cultural factors [6]—
for example discrepancies in patient selection criteria for
HHD between USA and Australia [3]. Differences in out-
come between modalities or in patient preferences do not
justify these variations and a study that canvassed patient
views found that about half would select PD if offered [7].
An important practice difference relates to the use of PD for
acute start dialysis [8], which is a common practice in Latin
America [9]. In Europe, however, PD is more likely to be
used if patients start dialysis in a planned way [10]. How-
ever, standards of patient care planning onto dialysis are a
major challenge, hampered by unpredictability and service
bottlenecks. Provision of information, education and sup-
port to make a modality choice that most suits the patient’s
lifestyle is inconsistent [11], although there are examples of
best practice that are inspiring [7]. Most patients do not
remember receiving much education about modality choice
and even if they did, they may not have the self-confidence
or resources to pursue their preference if it is not available
locally. This is particularly worrying since the transmission
of blood-borne viruses on HD units is a major concern in
many parts of the world [12].
Government intervention to manage modality use is no-
table in countries with higher PD use such as the ‘PD first’
policy in Hong Kong [13] and has been attempted region-
ally, for example a PD initiative in Ontario, Canada [14].
However, the success of target setting for PD usage is
limited by complex potential barriers to PD including the
availability of family support [15]. Despite per capita in-
come being related to the prevalence of RRT, this associ-
ation did not apply to HHD. Indeed, HHD is absent from
middle-income countries despite the stated cost-effectiveness
of the modality [16]. It seems that when left to market
forces, centre-based HD tends to predominate, possibly
because it fits best with business modelling. It is likely that
where physician reimbursement is related to the number
of patients occupying centre-based HD units, referrals
for home therapies become a disincentive. A growth in
nocturnal HHD in Australia followed alterations in re-
imbursement to incentivize the use of this modality. In
Finland, the increase in HHD followed several changes
including reimbursement as well as centralized training
and systematic identification of patients [3]. Recent
changes to reimbursement in the USA may have a pos-
itive impact on home therapies [17]. The Department of
Health in the UK is also in the process of developing a
tariff-based reimbursement system that will incentivize
the use of home therapies.
Capital costs of treatment set-up can be a barrier to HHD
that has greater impact in areas of the world where centre-
based dialysis costs are lowest due to low staffing costs or
standards of care. Even in the UK National Health Service,
obtaining capital for home set-up is challenging despite the
evidence of cost-effectiveness of HHD in the UK. It may be
that leasing smaller machines that do not require home adap-
tation will provide a solution. However, it is possible that
broadening patient selection criteria will lead to a reduction
in technique survival impacting on cost-effectiveness, if set-
up costs remain high. Median HHD technique survival in the
UK is only 18 months [18] just exceeding the 14 months
considered necessary to break even on set-up costs [19].
Do home modalities compete with each other for patients?
A study from Toronto General Hospital suggests otherwise
since the demographics of HHD patients on their programme
were significantly different to those on PD. HHD patients
tended to be younger and were more likely to be male than
PD patients, who were more likely to have diabetes or hyper-
tension [20]. Indeed, MacGregor et al. [16] noted a positive
association between the use of PD and HHD, although no
relation to transplantation rates. Baseline factors such as age
and co-morbidity have been demonstrated to have an impact
on selection for PD and HHD and clearly these vary consid-
erably from region to region [16, 21].
Historically, HHD was the predominant treatment in many
countries but increased RRT requirements led to the expan-
sion of facility-based dialysis, the development of satellite
dialysis units and the advent of continuous ambulatory peri-
toneal dialysis (reviewed in the Renal Association UK Home
Haemodialysis Working Party Document 2010 [22]). Geog-
raphy is an understandable factor that influences the choice
of home therapies, as living a significant distance from the
dialysis unit is a strong incentive to dialyse at home. How-
ever, its role as an overriding factor has been challenged by
the observation that Australia is a more urban country than
the USA (referenced in [3]). Accommodation arrangements
are clearly important both for storage of supplies for PD and
importantly to allow home adaptations for HHD. In the cities
of the world where floor space is at a premium, it is not
surprising that HHD is not popular and here, the newer
generation of smaller machines may have an impact.
There is evidence of improved outcomes for a range of
long-term conditions where patients are involved in self-
management [23, 24]. It has been observed that in many
spheres, home therapy is potentially a win–win situation—
offering better care at reduced cost [25]. Within the renal
domain, involving patients in their choice of dialysis modality
through good quality education leads to more patients se-
lecting self-care [26]. Would it be unreasonable to have an
international objective that each renal centre should offer
both hospital and home-based therapy in an unbiased way,
supporting shared decision making and encouraging patients
to have as much involvement as possible in their own care?
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